Dec 30, 2021

Mabwell Announced the First Person Dosed in the Phase I Study of First Anti-ST2 Antibody in China

➞

Dec 30, 2021

Honorary Qualification | Mabwell awarded as "Excellent Case" of Shanghai Industrial Talent Team Construction 2021

➞

Dec 22, 2021

The New Drug Application of Mabwell's Denosumab Injection Biosimilars 9MW0311 Was Accepted

➞

Dec 22, 2021

The New Drug Application of Mabwell's Denosumab Injection Biosimilars 9MW0321 Was Accepted

➞

Oct 21, 2021

Facilitate Development and Accelerate Progress | Shanghai OPCSTIC Visit Mabwell Bioscience to Research and Guide Work

➞

Oct 19, 2021

China's First Anti-Nectin-4 ADC Drug Receives IND Approval

➞

Oct 13, 2021

Honorary Qualification│Mabwell awarded the BIGStar 2021 Chinese Most Promising Innovative Biopharmaceutical Enterprises

➞

Sep 27, 2021

Mabwell Announced the First Patient Dosed in the Phase I Study of CD47/PD-L1 Bispecific Antibody

➞

Sep 22, 2021

Leaders of Shanghai Development and Reform Commission, Shanghai Municipal Commission of Economy and Informatization Technology and Finance Bureau of Shanghai make an on-site investigation to Mabwell

➞

Sep 17, 2021

Strive to Strengthen the Innovation Engine and Create a New Highland of Independent Innovation! Hang Yingwei, Director of Pudong New Area, and his team went to Mabwell for Investigation & Research

➞